Research programme: curcumin analogues - Traverse Biosciences

Drug Profile

Research programme: curcumin analogues - Traverse Biosciences

Alternative Names: CMC 2.24; TRB N0224

Latest Information Update: 20 Apr 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator State University of New York at Stony Brook
  • Developer The Feinstein Institute for Medical Research; Traverse Biosciences
  • Class Small molecules
  • Mechanism of Action Inflammation mediator inhibitors; Matrix metalloproteinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Neuroblastoma
  • Research Osteoarthritis

Most Recent Events

  • 20 Apr 2016 Preclinical trials in Neuroblastoma in USA (PO) prior to April 2016
  • 20 Apr 2016 Pharmacodynamics data from a preclinical trial in Neuroblastoma presented at the 107th Annual Meeting of the American Association for Cancer Research (AACR-2016)
  • 29 Jul 2014 Early research in Osteoarthritis in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top